First-line treatment with bendamustine and rituximab for old and frail patients with aggressive lymphoma : results of the B-R-ENDA trial / Friederike Braulke, Florian Zettl, Marita Ziepert, Andreas Viardot, Christoph Kahl, Gabriele Prange-Krex, Agnieszka Korfel, Martin Dreyling, Alexander Bott, Ulrich Wedding, Dietmar Reichert, Maike de Wit, Frank Hartmann, Viola Poeschel, Norbert Schmitz, Mathias Witzens-Harig, Wolfram Klapper, Andreas Rosenwald, Gerald Wulf, Bettina Altmann, Lorenz Trümper
The incidence of aggressive B-cell lymphomas increases with age, but for elderly or frail patients not eligible for doxorubicin-containing treatment standard therapy remains to be defined. In this prospective, multicenter, phase-2 B-R-ENDA trial, we investigated the feasibility, toxicity, and efficacy of 8 cycles rituximab combined with 6 cycles bendamustine (BR) in elderly or frail aggressive B-cell lymphoma patients: 39 patients aged >80 years and 29 patients aged 61-80 years with elevated Cumulative Illness Rating Scalescore >6 were included. Progression-free survival (PFS) and overall survival (OS) at 2 years were 45% (95% confidence interval [CI], 28%-61%) and 46% (28%-63%) for the patients age >80, as well 32% (13%-51%) and 37% (17%-57%) for frail patients age 64-80, respectively. In a preplanned retrospective analysis, we found no significant differences in PFS and OS comparing the outcome of the 39 patients age >80 years with 40 patients aged 76-80 years treated with 6xR-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) and 2 x rituximab in the RICOVER-60 trial (DSHNHL 1999-1, NCT00052936, EU-20243), yet we detected lower rates of infections and treatment-related deaths in the BR-treated patients. We demonstrate that older and frail patients with aggressive B-cell lymphoma who are not able to receive standard CHOP-based therapy can benefit from anthracycline-free therapy as a feasible and effective therapeutic option..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
Dec 1, 2022 2022 |
|---|---|
| Erschienen: |
Dec 1, 2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
HemaSphere - 6(2022), 12 vom: Dez., Artikel-ID e808, Seite 1-10 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Braulke, Friederike, 1979- [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Gesehen am 09.11.2023 |
|---|
| Umfang: |
Diagramme 10 |
|---|
| doi: |
10.1097/HS9.0000000000000808 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
1837269327 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | 1837269327 | ||
| 003 | DE-627 | ||
| 005 | 20231109142210.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230222s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/HS9.0000000000000808 |2 doi | |
| 035 | |a (DE-627)1837269327 | ||
| 035 | |a (DE-599)KXP1837269327 | ||
| 035 | |a (OCoLC)1389534068 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Braulke, Friederike |d 1979- |e verfasserin |0 (DE-588)131921509 |0 (DE-627)516081012 |0 (DE-576)267176988 |4 aut | |
| 245 | 1 | 0 | |a First-line treatment with bendamustine and rituximab for old and frail patients with aggressive lymphoma |b results of the B-R-ENDA trial |c Friederike Braulke, Florian Zettl, Marita Ziepert, Andreas Viardot, Christoph Kahl, Gabriele Prange-Krex, Agnieszka Korfel, Martin Dreyling, Alexander Bott, Ulrich Wedding, Dietmar Reichert, Maike de Wit, Frank Hartmann, Viola Poeschel, Norbert Schmitz, Mathias Witzens-Harig, Wolfram Klapper, Andreas Rosenwald, Gerald Wulf, Bettina Altmann, Lorenz Trümper |
| 264 | 1 | |c Dec 1, 2022 | |
| 300 | |b Diagramme | ||
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 09.11.2023 | ||
| 520 | |a The incidence of aggressive B-cell lymphomas increases with age, but for elderly or frail patients not eligible for doxorubicin-containing treatment standard therapy remains to be defined. In this prospective, multicenter, phase-2 B-R-ENDA trial, we investigated the feasibility, toxicity, and efficacy of 8 cycles rituximab combined with 6 cycles bendamustine (BR) in elderly or frail aggressive B-cell lymphoma patients: 39 patients aged >80 years and 29 patients aged 61-80 years with elevated Cumulative Illness Rating Scalescore >6 were included. Progression-free survival (PFS) and overall survival (OS) at 2 years were 45% (95% confidence interval [CI], 28%-61%) and 46% (28%-63%) for the patients age >80, as well 32% (13%-51%) and 37% (17%-57%) for frail patients age 64-80, respectively. In a preplanned retrospective analysis, we found no significant differences in PFS and OS comparing the outcome of the 39 patients age >80 years with 40 patients aged 76-80 years treated with 6xR-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) and 2 x rituximab in the RICOVER-60 trial (DSHNHL 1999-1, NCT00052936, EU-20243), yet we detected lower rates of infections and treatment-related deaths in the BR-treated patients. We demonstrate that older and frail patients with aggressive B-cell lymphoma who are not able to receive standard CHOP-based therapy can benefit from anthracycline-free therapy as a feasible and effective therapeutic option. | ||
| 700 | 1 | |a Zettl, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Ziepert, Marita |e verfasserin |4 aut | |
| 700 | 1 | |a Viardot, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Kahl, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Prange-Krex, Gabriele |e verfasserin |4 aut | |
| 700 | 1 | |a Korfel, Agnieszka |e verfasserin |4 aut | |
| 700 | 1 | |a Dreyling, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Bott, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Wedding, Ulrich |e verfasserin |4 aut | |
| 700 | 1 | |a Reichert, Dietmar |e verfasserin |4 aut | |
| 700 | 1 | |a de Wit, Maike |e verfasserin |4 aut | |
| 700 | 1 | |a Hartmann, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Poeschel, Viola |e verfasserin |4 aut | |
| 700 | 1 | |a Schmitz, Norbert |e verfasserin |4 aut | |
| 700 | 1 | |a Witzens-Harig, Mathias |e verfasserin |0 (DE-588)1050736516 |0 (DE-627)784812322 |0 (DE-576)404988970 |4 aut | |
| 700 | 1 | |a Klapper, Wolfram |e verfasserin |4 aut | |
| 700 | 1 | |a Rosenwald, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Wulf, Gerald |e verfasserin |4 aut | |
| 700 | 1 | |a Altmann, Bettina |e verfasserin |4 aut | |
| 700 | 1 | |a Trümper, Lorenz |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t HemaSphere |d [Philadelphia, Pennsylvania] : Wolters Kluwer Health, 2017 |g 6(2022), 12 vom: Dez., Artikel-ID e808, Seite 1-10 |h Online-Ressource |w (DE-627)1015324924 |w (DE-600)2922183-3 |w (DE-576)500571066 |x 2572-9241 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2022 |g number:12 |g month:12 |g elocationid:e808 |g pages:1-10 |g extent:10 |
| 856 | 4 | 0 | |u https://doi.org/10.1097/HS9.0000000000000808 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://journals.lww.com/hemasphere/Fulltext/2022/12000/First_line_Treatment_With_Bendamustine_and.12.aspx |x Verlag |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ILN_2013 | ||
| 912 | |a ISIL_DE-16-250 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_171 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_224 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_636 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2446 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2022 |e 12 |c 12 |i e808 |h 1-10 |g 10 | ||
| 980 | |2 2013 |1 01 |x DE-16-250 |b 4275485572 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 22-02-23 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 00 |s s |a hd2022 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 01 |s s |0 (DE-627)1410508463 |a wissenschaftlicher Artikel (Zeitschrift) | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 02 |s s |a per_21 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 03 |s s |a s_10 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s p |0 (DE-627)147498987X |a Witzens-Harig, Mathias | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)169133667X |a Zentrum für Innere Medizin (Krehl Klinik) | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)1416466967 |a Medizinische Fakultät Heidelberg | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |a pos_16 | ||